Overview
France specialty materials maker's Q1 sales fell 8% yr/yr on lower prices, negative currency effect
Adjusted EPS dropped 34% yr/yr as EBITDA declined 14%
Company maintains outlook for slight EBITDA growth in 2026 despite Middle East supply risks
Outlook
Arkema confirms target of slight EBITDA growth at constant currencies in 2026
Company expects major projects to deliver about €50 mln additional EBITDA in 2026
Arkema plans capital expenditure of around €600 mln in 2026
Result Drivers
REGIONAL DEMAND VARIATION - Growth in Asia and key markets like batteries and healthcare offset weak demand in Europe and North America
PRICING AND CURRENCY PRESSURE - Lower selling prices and negative currency effects weighed on sales and EBITDA
COST CONTROL AND PRICING ACTIONS - Ongoing cost management and swift pricing adjustments to address inflation and Middle East supply disruptions
Company press release: ID:nBw4sf7pXa
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
EUR 2.18 bln
Q1 Adjusted EPS
EUR 0.86
Q1 Adjusted Net Income
EUR 64.70 mln
Q1 EBITDA
EUR 282.70 mln
Q1 EBITDA Margin
13.00%
Q1 Net Debt
EUR 3.34 bln
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 9 "strong buy" or "buy", 7 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the specialty chemicals peer group is "buy."
Wall Street's median 12-month price target for Arkema SA is €62.00, about 1% below its May 5 closing price of €62.60
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 10 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)